scholarly journals The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: A decision analysis model

2016 ◽  
Vol 13 (3) ◽  
pp. 599-606 ◽  
Author(s):  
Ashleigh A. McGirr ◽  
Kevin L. Schwartz ◽  
Upton Allen ◽  
Melinda Solomon ◽  
Beate Sander
Keyword(s):  
Cystic Fibrosis ◽  
Cost Effectiveness ◽  
Decision Analysis ◽  
Decision Analysis Model ◽  
Analysis Model ◽  
Canadian Setting ◽  
The Cost

Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model

1993 ◽  
Vol 25 (2) ◽  
pp. 97-105 ◽  
Author(s):  
Bruce E. Hillner ◽  
Thomas J. Smith ◽  
Christopher E. Desch
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Decision Analysis ◽  
Early Breast Cancer ◽  
Decision Analysis Model ◽  
Analysis Model ◽  
Adjuvant Therapies ◽  
The Cost

Estimating the cost-effectiveness of stereotaxic biopsy for nonpalpable breast abnormalities: A decision analysis model

1996 ◽  
Vol 3 (4) ◽  
pp. 351-360 ◽  
Author(s):  
Bruce E. Hillner ◽  
Harry D. Bear ◽  
Laurie L. Fajardo
Keyword(s):  
Cost Effectiveness ◽  
Decision Analysis ◽  
Decision Analysis Model ◽  
Analysis Model ◽  
Stereotaxic Biopsy ◽  
The Cost

The Cost‐Effectiveness of Professional Doula Care for a Woman's First Two Births: A Decision Analysis Model

2019 ◽  
Vol 64 (4) ◽  
pp. 410-420
Author(s):  
Karen S. Greiner ◽  
Alyssa R. Hersh ◽  
Sally R. Hersh ◽  
Jesse M. Remer ◽  
Alexandra C. Gallagher ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Decision Analysis ◽  
Decision Analysis Model ◽  
Analysis Model ◽  
The Cost

Percutaneous Stenting of Incidental Unilateral Renal Artery Stenosis: Decision Analysis of Costs and Benefits

2003 ◽  
Vol 10 (3) ◽  
pp. 546-556 ◽  
Author(s):  
David A. Axelrod ◽  
A. Mark Fendrick ◽  
Ruth C. Carlos ◽  
Robert J. Lederman ◽  
James B. Froehlich ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Decision Analysis ◽  
Renal Artery ◽  
Incremental Cost ◽  
Renal Artery Stenosis ◽  
Cost Effective ◽  
Artery Stenosis ◽  
Decision Analysis Model ◽  
Analysis Model ◽  
Refractory Hypertension

Purpose: To determine the incremental cost-effectiveness of prophylactic percutaneous transluminal angioplasty with stent placement (PTA-S) in patients with incidentally discovered, asymptomatic renal artery stenosis (RAS) compared to delaying PTA-S until patients develop refractory hypertension or renal insufficiency (therapeutic PTA-S). Methods: The Markov decision analysis model was used to determine the incremental cost per quality adjusted life year (QALY) saved for prophylactic PTA-S as compared to therapeutic PTA-S in a hypothetical cohort of patients with 50% unilateral atherosclerotic RAS followed from age 61 to death. Results: Prophylactic PTA-S compared to therapeutic PTA-S results in more QALYs/patient (10.9 versus 10.3) at higher lifetime costs ($23,664 versus $16,558). The incremental cost effectiveness of prophylactic PTA-S was estimated to be $12,466/QALY. Prophylactic stenting was not cost effective (>$50,000/QALY) if the modeled incidence of stent restenosis exceeded 15%/year and the incidence of progression in the contralateral renal artery was <2% of arteries/year. Conclusions: PTA-S of incidental, asymptomatic unilateral RAS may improve patients' quality of life at an acceptable incremental cost. However, this technology should be used hesitantly until a randomized comparison confirms its effectiveness.

Meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus

Neurology ◽  
2019 ◽  
Vol 92 (20) ◽  
pp. e2339-e2348 ◽  
Author(s):  
Iván Sánchez Fernández ◽  
Marina Gaínza-Lein ◽  
Nathan Lamb ◽  
Tobias Loddenkemper
Keyword(s):  
Status Epilepticus ◽  
Cost Effectiveness ◽  
Antiepileptic Drugs ◽  
Meta Analysis ◽  
Cost Effective ◽  
Sensitivity Analyses ◽  
Convulsive Status Epilepticus ◽  
Decision Analysis Model ◽  
Analysis Model ◽  
The Cost

ObjectiveCompare the cost and effectiveness of nonbenzodiazepine antiepileptic drugs (non-BZD AEDs) for treatment of BZD-resistant convulsive status epilepticus (SE).MethodsDecision analysis model populated with effectiveness data from a systematic review and meta-analysis of the literature, and cost data from publicly available prices. The primary outcome was cost per seizure stopped ($/SS). Sensitivity analyses evaluated the robustness of the results across a wide variation of the input parameters.ResultsWe included 24 studies with 1,185 SE episodes. The most effective non-BZD AED was phenobarbital (PB) with a probability of SS of 0.8 (95% confidence interval [CI]: 0.69–0.88), followed by valproate (VPA) (0.71 [95% CI: 0.61–0.79]), lacosamide (0.66 [95% CI: 0.51–0.79]), levetiracetam (LEV) (0.62 [95% CI: 0.5–0.73]), and phenytoin/fosphenytoin (PHT) (0.53 [95% CI: 0.39–0.67]). In pairwise comparisons, PB was more effective than PHT (p = 0.002), VPA was more effective than PHT (p = 0.043), and PB was more effective than LEV (p = 0.018). The most cost-effective non-BZD AED was LEV (incremental cost-effectiveness ratio [ICER]: $18.55/SS), followed by VPA (ICER: $94.44/SS), and lastly PB (ICER: $847.22/SS). PHT and lacosamide were not cost-effective compared to the other options. Sensitivity analyses showed marked overlap in cost-effectiveness, but PHT was consistently less cost-effective than LEV, VPA, and PB.ConclusionVPA and PB were more effective than PHT for SE. There is substantial overlap in the cost-effectiveness of non-BZD AEDs for SE, but available evidence does not support the preeminence of PHT, neither in terms of effectiveness nor in terms of cost-effectiveness.

scholarly journals Assessment of the Clinical and Economic Impact of Different Immunization Protocols of Measles, Mumps, Rubella and Varicella in Internationally Adopted Children

Vaccines ◽  
2020 ◽  
Vol 8 (1) ◽  
pp. 60 ◽  
Author(s):  
Sara Boccalini ◽  
Angela Bechini ◽  
Cecilia Maria Alimenti ◽  
Paolo Bonanni ◽  
Luisa Galli ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Economic Impact ◽  
Minimum Cost ◽  
Point Of View ◽  
Decision Analysis Model ◽  
Adopted Children ◽  
Analysis Model ◽  
Internationally Adopted Children ◽  
The Cost ◽  
Internationally Adopted

The appropriate immunization of internationally adopted children (IAC) is currently under debate and different approaches have been suggested. The aim of this study is to evaluate the clinical and economic impact of different strategies of measles, mumps, rubella, and varicella (MMRV) immunization in IAC in Italy. A decision analysis model was developed to compare three strategies: presumptive immunization, pre-vaccination serotesting and vaccination based on documentation of previous immunization. Main outcomes were the cost of strategy, number of protected IAC, and cost per child protected against MMRV. Moreover, the incremental cost-effectiveness ratio (ICER) was calculated. The strategy currently recommended in Italy (immunize based on documentation) is less expensive. On the other hand, the pre-vaccination serotesting strategy against MMRV together, improves outcomes with a minimum cost increase, compared with the presumptive immunization strategy and compared with the comparator strategy. From a cost-effectiveness point of view, vaccination based on serotesting results in being the most advantageous strategy compared to presumptive vaccination. By applying a chemiluminescent immunoassay test, the serology strategy resulted to be clinically and economically advantageous. Similar results were obtained excluding children aged <1 year for both serology methods. In conclusion, based on our analyses, considering MMRV vaccine, serotesting strategy appears to be the preferred option in IAC.

scholarly journals PCN101 COST-EFFECTIVENESS OF SHORT-ACTING OPIOIDS FOR BREAKTHROUGH PAIN IN CANCER PATIENTS—A SCOTTISH-BASED DECISION-ANALYSIS MODEL

2009 ◽  
Vol 12 (7) ◽  
pp. A276
Author(s):  
D Vissers ◽  
W Stam ◽  
K Tolley ◽  
V Sendersky ◽  
JP Jansen
Keyword(s):  
Cost Effectiveness ◽  
Decision Analysis ◽  
Cancer Patients ◽  
Breakthrough Pain ◽  
Decision Analysis Model ◽  
Analysis Model ◽  
Short Acting
Sign in / Sign up

Export Citation Format

Share Document